Table 1: Nycomed: PharmaVitae forecasts at a glance 7
Table 2: Nycomed's financial transformation ($m), 2001-07 10
Table 3: Nycomed quarterly global sales update ($m), Q4 2008 24
Table 4: Nycomed key product developments, Q1 2008 26
Table 5: Nycomed product deals and alliances, Q1 2008 27
Table 6: Nycomed technology deals and alliances, Q1 2008 27
Table 7: Nycomed M&A activity, Q1 2008 28
Table 8: Nycomed company announcements, Q1 2008 28
Table 9: Nycomed future product milestones, 2008-10 29
Table 10: Nycomed product portfolio overview ($m), 2001-07 38
Table 11: Nycomed product portfolio overview ($m), 2007-13 40
Table 12: Nycomed product portfolio overview ($m), 2001-07 45
Table 13: Nycomed product portfolio overview ($m), 2007-13 49
Table 14: Nycomed portfolio overview by geographic region ($m), 2001-07 54
Table 15: Nycomed portfolio overview by geographic region ($m), 2007-13 56
Table 16: Nycomed launch portfolio overview ($m), 2007-13 60
Table 17: Nycomed core portfolio overview ($m), 2007-13 61
Table 18: Nycomed expiry portfolio overview ($m), 2007-13 62
Table 19: Nycomed portfolio overview by molecule type ($m), 2001-07 65
Table 20: Nycomed portfolio overview by molecule type ($m), 2007-13 66
Table 21: Nycomed product portfolio overview by source ($m), 2001-07 69
Table 22: Nycomed product portfolio overview by source ($m), 2007-13 71
Table 23: Total Nycomed sales by business unit ($m), 2001-07 74
Table 24: Nycomed profit and loss account ($m), 2001-07 75
Table 25: Nycomed balance sheet ($m), 2001-07 77
Table 26: Nycomed operating revenue/cost analysis ($m), 2001-07 79
Table 27: Nycomed operating cost ratio analysis (% of total revenues), 2001-07 80
Table 28: Nycomed operating cost ratio analysis (% of total revenues), 2007-13 81
Table 29: Nycomed operating revenue/cost analysis ($m), 2007-13 83
Table 30: Nycomed capital employed ($m), 2001-07 85
Table 31: Nycomed EBIT return on capital employed ($m), 2001-07 87
Table 32: Nycomed EBIT pre-tax return/capital employed driver analysis (%), 2001-07 88
Table 33: Key products overview 91
Table 34: Pantoprazole: overview 93
Table 35: Pantoprazole: sales forecast ($m), 2007-13 94
Table 36: Alvesco: overview 99
Table 37: Omnaris: overview 100
Table 38: Alvesco: sales forecast ($m), 2007-13 101
Table 39: Omnaris: sales forecast ($m), 2007-13 101
Table 40: Preotact: overview 107
Table 41: Preotact: sales forecast ($m), 2007-13 108
Table 42: Calcichew: overview 110
Table 43: Calchew: sales forecast ($m), 2007-13 111
Table 44: Actovegin: overview 112
Table 45: Actovegin: sales forecast ($m), 2007-13 113
Table 46: Nycomed's R&D pipeline (Phase I-registration) 114
Table 47: Exchange rates, 2007 117
Figure 1: Nycomed prescription pharmaceutical performance, sales ($m) and growth rate (%), 2001-13 5
Figure 2: Nycomed's financial performance ($m), 2001-13 6
Figure 3: Nycomed's operating performance transformed over 2005-07 8
Figure 4: Pantoprazole expiry prevents profit expanion 11
Figure 5: Nycomed sales by geography ($m), 2006 13
Figure 6: Nycomed sales by geography ($m), 2007 14
Figure 7: Nycomed SWOT analysis 16
Figure 8: Top 10 product sales ($m), forecast vs. actual, 2008 25
Figure 9: Nycomed prescription pharmaceutical performance, sales ($m) and growth rate (%), 2001-13 35
Figure 10: Nycomed key sales growth driver & resistors ($m), 2001-07 39
Figure 11: Nycomed key sales growth drivers & resistors ($m), 2007-13 41
Figure 12: Nycomed prescription pharmaceutical sales by therapy area ($m), 2001-13 44
Figure 13: Nycomed prescription pharma sales by therapy area (% of total), 2001-13 52
Figure 14: Nycomed prescription pharmaceutical sales by geographic region ($m), 2001-13 53
Figure 15: Nycomed growth drivers and resistors by geographic region ($m), 2001-07 54
Figure 16: Nycomed drivers and resistors by geographic region ($m), 2007-13 56
Figure 17: Nycomed prescription pharmaceutical sales by geographic region (% of total), 2001-13 58
Figure 18: Nycomed launch/core/expiry configuration ($m), 2007-13 63
Figure 19: Nycomed prescription pharmaceutical sales by molecule type ($m), 2001-13 64
Figure 20: Nycomed growth drivers and resistors by molecule type ($m), 2007-13 66
Figure 21: Nycomed prescription pharmaceutical sales by source ($m), 2001-13 68
Figure 22: Nycomed growth drivers and resistors by source ($m), 2001-07 69
Figure 23: Nycomed growth drivers and resistors by source ($m), 2007-13 71
Figure 24: Nycomed operating revenue/cost analysis ($m), 2001-13 78
Figure 25: Nycomed operating cost ratio analysis (% of total revenues), 2001-13 82
Figure 26: Nycomed return on capital employed, EBIT margin and capital turnover, 2001-07 84
Figure 27: Return on capital employed formula 88
[Tabellenverzeichnis ausblenden]
